Whalesbook
FDA Approval Meets Mixed Market Response
Lupin Pharmaceuticals announced Wednesday, May 13, 2026, that it received US FDA approval for its Famotidine Injection USP. This approval covers 20 mg/2 mL single-dose vials, making Lupin a supplier of a generic version of Merck's Pepcid Injection. The drug is approved for intravenous use in hospitalized patients needing treatment for conditions causing excessive stomach acid or difficult-to-treat ulcers, and for those who cannot take oral medication.
Famotidine Injection targets an estimated annual US market of $8.7 million. While this expands Lupin's complex generics and injectables portfolio, the market's reaction was subdued. The stock closed down 1.36% on the BSE, despite the regulatory and financial news. This muted response suggests investors are weighing the modest revenue potential of this approval against the company's overall performance or broader market trends. Lupin's US business is projected to sustain over $1 billion in revenue, driven by biosimilars and its specialty portfolio.
Strong Financials Show Robust Growth
The company's financial results for the January-March quarter of FY26 showed strong growth. Lupin nearly doubled its consolidated net profit year-on-year to ₹1,460 crore, a 97% increase. Revenue from operations surged by 31.9% to ₹7,475 crore. This performance was driven by exceptional results in its US generics business and growth across global markets. For the full fiscal year 2026, consolidated net profit grew 62.5% to ₹5,333 crore, with revenue up 23.1% to ₹27,958 crore. The company's market capitalization is approximately ₹1.01-1.09 trillion, and its P/E ratio is in the mid-20s.
Strategy Focuses on High-Margin Injectables Amid Competition
Lupin's move into the famotidine injectable market follows a wider industry trend of pharmaceutical companies shifting from low-margin oral generics to higher-margin injectables. The US generic sterile injectable market is substantial, projected for significant growth. Estimates suggest its value could reach over $23 billion in 2026 and $38 billion to $48 billion by 2034, with compound annual growth rates between 7.95% and 11%. Lupin's strategic focus on complex generics and injectables is key to managing pricing pressures in oral generics.
However, Lupin operates in a competitive market. Rivals in US generics and injectables include Cipla, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Zydus Lifesciences. While Lupin ranks third in US generics by prescription volume, the famotidine injection approval faces competition and adds to its existing product lineup. Historically, Lupin's stock has reacted mildly to regulatory approvals. In May 2025, shares traded flat to lower after USFDA approvals for Raltegravir Tablets and Eslicarbazepine Acetate Tablets. This pattern suggests that regulatory wins, while positive, may have limited immediate stock impact, particularly when market expectations are already high or larger growth drivers are awaited.
Modest Opportunity and Past Scrutiny Temper Enthusiasm
The estimated $8.7 million market size for Famotidine Injection represents a modest revenue opportunity. While it expands Lupin's injectable portfolio, it is unlikely to be a significant standalone revenue driver. Investors may be seeking larger market opportunities or more substantial contributions from new launches. Furthermore, Lupin has faced regulatory scrutiny; in September 2025, its share price declined after the US FDA issued observations following an inspection of its Nagpur manufacturing unit. Although the company committed to addressing these, such events can concern investors, especially when manufacturing facilities are critical for product supply, as with this famotidine injection.
Adding to investor caution, some analysts have reportedly downgraded Lupin shares to 'Hold' despite strong earnings. This suggests a view that current valuations may already reflect future growth or that margin pressures and competition are impacting sentiment. Lupin's strategy to shift its portfolio towards higher-complexity assets like injectables is a sound long-term approach. However, the immediate impact of individual approvals like famotidine injection may not be enough to overcome these broader market perceptions.
Complex Generics Pipeline Drives Future Growth
Lupin's strategic direction towards complex generics and injectables is critical for sustained growth and margin expansion in a competitive pharmaceutical environment. The company's ability to secure approvals for these higher-value products will be key to improving its stock valuation. Future performance will depend on the successful commercialization of its pipeline and its capacity to navigate regulatory compliance and competitive challenges in major markets, particularly the United States.